Table 3

Whole Blood Clinical Chemistry Markers

300 mg
 600 mg
Week
 0
 1
 3
 8
 11
 0
 1
 3
 8
 11
WBC (K/μL)
 5.3 ± 1.6
 5.0 ± 1.1
 5.3 ± 1.7
 5.2 ± 2.0
 4.5 ± 1.5
 5.5 ± .96
 4.6 ± .91
 5.0 ± 1.0
 4.9 ± .67
 5.1 ± .84
RBC (M/μL)
 5.0 ± .51
 5.0 ± .50
 4.6 ± .84
 5.0 ± .37
 4.9 ± .46
 5.2 ± .37
 5.1 ± .33
 5.2 ± .24
 4.9 ± 1.2
 5.3 ± .30
Hemoglobin (g/dL)
 15 ± 1.1
 15 ± 1.1
 15 ± 1.2
 15 ± .59
 15 ± 1.0
 15 ± .95
 15 ± .93
 15 ± .63
 15 ± .66
 15 ± .78
Hematocrit (%)
 44 ± 3.5
 44 ± 3.7
 44 ± 3.6
 45 ± 2.4
 43 ± 3.3
 46 ± 3.0*
 44 ± 2.3*
 45 ± 1.9*
 46 ± 2.1*
 46 ± 2.7*
MCV (fL)
 88 ± 2.8
 88 ± 2.8
 88 ± 2.4
 89 ± 2.4
 89 ± 2.9
 87 ± 2.7
 86 ± 2.8
 87 ± 2.6
 87 ± 2.3
 87 ± 2.5
MCH (pg)
 30 ± 1.2
 30 ± 1.3
 30 ± 1.0
 30 ± 1.3
 30 ± 1.0
 29 ± 1.0
 29 ± .95
 29 ± .98
 29 ± 1.1
 29 ± .78
MCHC (g/dL)
 34 ± .69
 34 ± .76
 34 ± .64
 33 ± .78
 34 ± .81
 33 ± .60
 34 ± .85
 33 ± .56
 33 ± .61
 34 ± .60
Neutrophils
 2.9 ± 1.0
 2.5 ± .43
 2.9 ± 1.1
 2.8 ± 1.0
 2.3 ± 1.1
 2.8 ± .52
 2.4 ± .47
 2.6 ± .66
 2.5 ± .29
 2.9 ± 1.1
Lymphocytes
 1.7 ± .51
 1.9 ± .84
 1.7 ± .62
 1.8 ± .87
 1.6 ± .69
 2.0 ± .39
 1.6 ± .39
 1.8 ± .50
 1.7 ± .44
 1.8 ± .44
Monocytes
 .45 ± .12
 .39 ± .12
 .44 ± .12
 .36 ± .07
 .37 ± .14
 .43 ± .14*
 .38 ± .04*
 .39 ± .13*
 .40 ± .09*
 .44 ± .12*
Eosinophils
 .12 ± .06
 .13 ± .08
 .11 ± .05
 .12 ± .06
 .12 ± .06
 .14 ± .08
 .14 ± .09
 .16 ± .10
 .16 ± .09
 .16 ± .07
Basophils
 .06 ± .02
 .05 ± .01
 .05 ± .01
 .05 ± .01
 .05 ± .02
 .07 ± .02*
 .06 ± .02*
 .07 ± .02*
 .07 ± .01*
 .06 ± .01*

* Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines values that persisted throughout the study, and was apparently independent of 6-OXO supplementation.

Rohle et al. Journal of the International Society of Sports Nutrition 2007 4:13   doi:10.1186/1550-2783-4-13